The Pfizer share price vaccine boost

On November 9 the Pfizer share price not only received a shot in the arm from the company’s own groundbreaking COVID-19 vaccine news. It also boosted world stock markets as well as the Pfizer share price. Part of the enthusiasm for the 90% effective / store at -70 centigrade vaccine was clearly the relief of the announcement marking the beginning of the end of the pandemic, both in terms of victims and economies.

The news could be even more of a breakthrough if as Pfizer has promised it can turn the vaccine into a powder, sidestepping the ultra cold storage issue. However, digging deeper into the news it could be argued that it raises as many questions as it answers for the Pfizer share price. Who will win the COVID-19 vaccine race, as well as what the financial benefits may be to Pfizer shares?

Learn more about shares trading with ATFX

 

CEO Albert Bourla sells Pfizer shares

One of the events that added spice to the Pfizer’s vaccine news was the simultaneous sale on the day of $5.6m worth of Pfizer shares by the CEO of the company. Given the way that share dealings by company executives are one of the most important signals to investors, the timing here for the PFE share price was unfortunate to say the least. In fact, Pfizer said that the deal had been set up as long ago as August, via an automated price limit.

However, the fact that the stock only rose 15% at the peak on the day can be explained by the way that the Pfizer shares sale by the CEO damaged sentiment, albeit inadvertently. Nevertheless, rather than sentiment surrounding the news, it was the prospects for the company after the development of the vaccine which were key for investors.

 

How much could Pfizer shares gain from a COVID-19 vaccine?

There are two key factors for Pfizer with regard to a COVID-19 vaccine. The first is how effective the vaccine is itself. But perhaps more importantly in the wake of Moderna’s 94.5% effective vaccine, whether the COVID-19 vaccine battle will become a race with two or even more horses? If this is the case the estimates in terms of earnings could become far more complex than they may appear currently.

Current estimates are that Pfizer and partner BioNTech could make up to 1.3bn vaccine doses by the end of 2021. This may make up for the fact that aside from a COVID-19 vaccine the Pfizer share price has been pressured by year on year sales actually declining over the past six quarters. The prospect of this slide being halted could boost Pfizer shares, if the competition from subsequent vaccines such as the latest from Moderna do not undermine its offering.

 

Pfizer shares need a COVID-19 vaccine boost

While the arrival of its COVID-19 vaccine is welcome, it is clear that it is timely as well. Across Pfizer’s portfolio in recent years we have seen blockbuster drugs fail relative to rivals. This was particularly underlined in the summer of 2020 with the relative disappointment associated with its breast cancer test Ibrance relative to that of rival Eli Lilly.

 

How to trade Pfizer shares

Open a live or demo account with ATFX to get started today. Trade shares on leverage, take up a long or short position when trading with CFDs and make potential gains from price movements.

1. Register for an account or log in to your existing account

2. Open MT4 either on your desktop or mobile

3. Search for Pfizer shares in the market watch or symbols window

4. Choose your position size

5. Hit buy or sell, and then confirm the trade

 

PFE share price daily chart

Daily chart analysis showing Pfizer share price daily movements for 2020

 

Looking to learn trading strategies to boost your trading? Check out our Trading Education Center.

Take the opportunity to develop your trading skills with our free educational resources. Find e-books, in-depth trading courses, MT4 platform guideline videos, trading strategies and more.

Recent News
Start Trading Now!

Try our demo account for free to learn trading. When you’re ready, switch to the live account and start trading for real.

Popular posts

ATFX

The Firm has taken the decision to cease providing services to retail clients, with immediate effect. We are therefore unable to accept any applications.

Services to professional clients will not be impacted. For professional applications please contact [email protected]

ATFX

Restrictions on Use

Products and Services on this website https://www.atfx.com/en-ae/ are not suitable
in your country. Such information and materials should not be regarded as or
constitute a distribution, an offer, or a solicitation to buy or sell any investments.
Please visit https://www.atfx.com/en/ to proceed.

ATFX

使用限制

本网站的产品及服务不适合英国居民。网站内部的信息和素材不应被视为分销,要约,买入或卖出任何投资产品。请继续访问 https://www.atfx.com/en/

ATFX

Restrictions on Use

Products and Services on this website are not suitable for the UK residents. Such information and materials should not be regarded as or constitute a distribution, an offer, or a solicitation to buy or sell any investments. Please visit https://www.atfx.com/en/ to proceed.

ATFX

Restrictions on Use

Products and Services on this website are not suitable for the UK residents. Such information and materials should not be regarded as or constitute a distribution, an offer, or a solicitation to buy or sell any investments. Please visit https://www.atfx.com/en/ to proceed.

ATFX

Restrictions on Use

Products and Services on this website are not suitable for Hong Kong residents. Such information and materials should not be regarded as or constitute a distribution, an offer, solicitation to buy or sell any investments.

使用限制: 本網站的產品及服務不適合香港居民使用。網站內部的信息和素材不應被視為分銷,要約,買入或賣出任何投資產品。

ATFX

Restrictions on Use

AT Global Markets (UK) Limited does not offer trading services to retail clients.
If you are a professional client, please visit https://www.atfxconnect.com/